Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
RO7496998
Atea Pharmaceuticals
COVID-19
1 trial -
ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease (ASCVD)
1 trial -
ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN
Novartis Pharmaceuticals
Non-obstructive Coronary Artery Disease
1 trial -
Ramosetron
Astellas Pharma Inc
Vomiting
1 trial -
Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.
ISTA Pharma Limited
knee osteoarthritis
1 trial -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity (ROP)
1 trial -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity
1 trial -
Ranibizumab 0.5 mg
Novartis Pharmaceuticals
Central Retinal Vein Occlusion
1 trial -
Rapastinel
Allergan Pharmaceuticals International Limited
Depressive Disorder, Major
1 trial -
Rasagiline
Teva Pharma GmbH
Progressive Supranuclear Palsy
1 trial -
Recombinant Anti-IL-1ฮฒ Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Recombinant Human VEGF Receptor-Fc Fusion Protein
Biotech Pharmaceutical Co.,
Neovascular Age-related Macular Degeneration
1 trial -
Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Livzon Pharmaceutical Group
COVID-19 Pandemic
1 trial -
Remibrutinib
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
Remibrutinib
Novartis Pharmaceuticals
Chronic Inducible Urticaria
1 trial -
Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)
Pari Pharma GmbH
Remyelination in Multiple Sclerosis
1 trial -
Reslizumab
Teva Pharma GmbH
Eosinophilic Asthma
5 trials -
Reslizumab
Teva Pharma GmbH
Severe Persistent Asthma
1 trial -
Resmetirom
Madrigal Pharmaceuticals EU Limited
Non-Alcoholic Fatty Liver Disease
1 trial -
Resmetirom
Madrigal Pharmaceuticals EU Limited
NASH
1 trial -
Revatio 0.8 mg/ml solution for injection
Pari Pharma GmbH
Hypoxic ischemic encephalopathy
1 trial -
Revefenacin
Theravance Biopharma Ireland Umited
Chronic Obstructive Pulmonary Disease, COPD
2 trials -
Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s
Incyte
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
1 trial -
Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARMยฎ, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources